Redenlab awarded new clinical trial with Top 10 Pharma company
Redenlab Inc. are pleased to announce securing clinical trial in Cyclic Vomiting Syndrome with a Top 10 pharma company. Redenlab are providing audio capture and analytics for a Phase 1b clinical trial. Conducted in sites across the USA, the study will investigate the efficacy of a treatment designed to ameliorate the impact of this rare and debilitating condition.
Redenlab’s Science lead Gustavo Noffs MD PhD had this to say about the study:
“We are leveraging our existing expert capabilities in voice capture and analysis to help monitor the debilitating impact of this condition. This is a practical example of crosstalk between disciplines. It’s a great opportunity to learn, and to rigorously advance our audio technology to benefit new populations.”
Cyclic vomiting syndrome is characterized by episodes of severe vomiting that have no apparent cause. Episodes can last for hours or days and alternate with symptom-free periods. Episodes are similar, meaning that they tend to start at the same time of day, last the same length of time, and occur with the same symptoms and intensity.
Cyclic vomiting syndrome occurs in all age groups, though it often begins in children around 3 to 7 years old. Although it’s more common in children, the number of cases diagnosed in adults is increasing.
The syndrome is difficult to diagnose because vomiting is a symptom of many disorders. Treatment often involves lifestyle changes to help prevent the events that can trigger vomiting episodes. Medications, including anti-nausea and migraine therapies, may help lessen symptoms.
Click here for more details on CVS.